Market Lifecycle Stage
The global polycythemia vera market is currently in the growth stage of its lifecycle. While polycythemia vera remains a rare disease, the market is experiencing increasing awareness, improved diagnostic capabilities, and advancements in treatment options, particularly with the introduction of targeted therapies such as JAK2 inhibitors and RNA-targeted medicines. These innovations are helping address unmet needs in polycythemia vera management, driving market expansion.
Additionally, regulatory incentives such as orphan drug designation are encouraging more companies to enter the market, further fueling growth. The market is also benefiting from increasing healthcare access in emerging regions and the growing focus on personalized medicine. However, it is still developing in terms of market penetration, especially in less-represented areas, indicating a strong potential for continued growth in the coming years.
Impact
Increasing demand for polycythemia vera therapies is anticipated to support the growth of the global polycythemia vera market during the forecast period 2025-2035.
The global polycythemia vera market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline.
Market Segmentation:
Segmentation 1: by Region
North America
Europe
Asia-Pacific
Rest-of-the-World
North America is expected to dominate the global polycythemia vera market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global polycythemia vera market.
Recent Developments
Partnerships: In March 2025, Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd. announced that they had entered into a license agreement granting Ono exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera.
Regulatory Activities: In March 2025, ANVISA approved BESREMi (ropeginterferon alfa-2b) for the treatment of adult patients with polycythemia vera.
Regulatory Activities: In January 2025, VGT-1849A, an antisense oligonucleotide-based novel Janus kinase 2 (JAK2) inhibitor, received Orphan Drug Designation from the FDA for the management of polycythemia vera.
Demand – Drivers and Limitations
The following are the drivers for the global polycythemia vera market:
Increasing Prevalence of Polycythemia Vera
Rising Awareness and Advancements in Diagnostic Technologies
The global polycythemia vera market is expected to face some limitations too, due to the following challenges:
High Treatment Costs
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: Innovations in the global polycythemia vera market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Ionis Pharmaceuticals, Inc. and Vanda Pharmaceuticals, have been involved in the development of therapies for polycythemia vera.
Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.
Some of the prominent names established in this market are:
Novartis AG
Merck
Protagonist Therapeutics, Inc.
Mabwell Bioscience Co., Ltd.
Silence Therapeutics plc
PharmaEssentia
AOP Orphan Pharmaceuticals AG
Incyte Corporation
Ionis Pharmaceuticals, Inc.
Hoffmann-La Roche
Vanda Pharmaceuticals
Ono Pharmaceutical Co., Ltd.
Takeda
Pint Pharma
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Executive Summary
- Scope of Study
- 1. Global Polycythemia Vera Market Overview
- 1.1 Industry Outlook
- 1.1.1 Introduction
- 1.1.2 Market Overview and Ecosystem
- 1.1.3 Epidemiological Analysis of Polycythemia Vera
- 1.1.3.1 By Region
- 1.1.3.1.1 U.S.
- 1.1.3.1.2 EU5
- 1.1.3.1.3 Rest-of-the-World
- 1.1.3.2 By Age Group
- 1.1.4 Market Trends
- 1.1.5 Regulatory Landscape / Compliance
- 1.1.5.1 Legal Requirement and Framework in the U.S.
- 1.1.5.2 Legal Requirement and Framework in the E.U.
- 1.1.5.3 Legal Requirement and Framework in Asia-Pacific
- 1.1.5.4 Legal Requirement and Framework in Rest-of-the-World
- 1.1.6 Pipeline Analysis
- 1.1.6.1 Drug
- 1.1.6.1.1 Description
- 1.1.6.1.2 Clinical development
- 1.1.6.1.3 Safety and Efficacy
- 1.2 Market Dynamics
- 1.2.1 Market Drivers
- 1.2.1.1 Impact Analysis
- 1.2.2 Market Restraints
- 1.2.2.1 Impact Analysis
- 1.2.3 Market Opportunities
- 2. Global Polycythemia Vera Market (By Region), $Million, 2023-2035
- 2.1 North America
- 2.1.1 Market Dynamics
- 2.1.1.1 Impact Analysis
- 2.1.2 Market Sizing and Forecast
- 2.1.2.1 North America Polycythemia Vera Market (by Country)
- 2.1.2.1.1 U.S.
- 2.1.2.1.2 Canada
- 2.2 Europe
- 2.2.1 Market Dynamics
- 2.2.1.1 Impact Analysis
- 2.2.2 Market Sizing and Forecast
- 2.2.2.1 Europe Polycythemia Vera Market (by Country)
- 2.2.2.1.1 U.K.
- 2.2.2.1.2 Germany
- 2.2.2.1.3 France
- 2.2.2.1.4 Italy
- 2.2.2.1.5 Spain
- 2.3 Asia-Pacific
- 2.3.1 Market Dynamics
- 2.3.1.1 Impact Analysis
- 2.3.2 Market Sizing and Forecast
- 2.3.2.1 Asia-Pacific Polycythemia Vera Market (by Country)
- 2.3.2.1.1 Japan
- 2.3.2.1.2 China
- 2.4 Rest-of-the-World
- 2.4.1 Market Dynamics
- 2.4.2 Market Size and Forecast
- 3. Global Polycythemia Vera Market - Competitive Benchmarking and Company Profiles
- 3.1 Competitive Landscape
- 3.1.1 Key Strategies and Developments by Company
- 3.1.1.1 Funding Activities
- 3.1.1.2 Mergers and Acquisitions
- 3.1.1.3 Regulatory Approvals
- 3.1.1.4 Partnerships, Collaborations and Business Expansions
- 3.1.2 Key Developments Analysis
- 3.2 Company Profiles
- 3.2.1 Novartis AG
- 3.2.1.1 Company Overview
- 3.2.1.2 Product Portfolio
- 3.2.1.3 Target Customers/End Users
- 3.2.1.4 Analyst View
- 3.2.2 Merck
- 3.2.2.1 Company Overview
- 3.2.2.2 Product Portfolio
- 3.2.2.3 Target Customers/End Users
- 3.2.2.4 Analyst View
- 3.2.3 Protagonist Therapeutics, Inc.
- 3.2.3.1 Company Overview
- 3.2.3.2 Product Portfolio
- 3.2.3.3 Target Customers/End Users
- 3.2.3.4 Analyst View
- 3.2.4 Mabwell Bioscience Co., Ltd.
- 3.2.4.1 Company Overview
- 3.2.4.2 Product Portfolio
- 3.2.4.3 Target Customers/End Users
- 3.2.4.4 Analyst View
- 3.2.5 Silence Therapeutics plc
- 3.2.5.1 Company Overview
- 3.2.5.2 Product Portfolio
- 3.2.5.3 Target Customers/End Users
- 3.2.5.4 Analyst View
- 3.2.6 PharmaEssentia
- 3.2.6.1 Company Overview
- 3.2.6.2 Product Portfolio
- 3.2.6.3 Target Customers/End Users
- 3.2.6.4 Analyst View
- 3.2.7 AOP Orphan Pharmaceuticals AG
- 3.2.7.1 Company Overview
- 3.2.7.2 Product Portfolio
- 3.2.7.3 Target Customers/End Users
- 3.2.7.4 Analyst View
- 3.2.8 Incyte Corporation
- 3.2.8.1 Company Overview
- 3.2.8.2 Product Portfolio
- 3.2.8.3 Target Customers/End Users
- 3.2.8.4 Analyst View
- 3.2.9 Ionis Pharmaceuticals, Inc.
- 3.2.9.1 Company Overview
- 3.2.9.2 Product Portfolio
- 3.2.9.3 Target Customers/End Users
- 3.2.9.4 Analyst View
- 3.2.10 Hoffmann-La Roche
- 3.2.10.1 Company Overview
- 3.2.10.2 Product Portfolio
- 3.2.10.3 Target Customers/End Users
- 3.2.10.4 Analyst View
- 3.2.11 Vanda Pharmaceuticals
- 3.2.11.1 Company Overview
- 3.2.11.2 Product Portfolio
- 3.2.11.3 Target Customers/End Users
- 3.2.11.4 Analyst View
- 3.2.12 Ono Pharmaceutical Co., Ltd.
- 3.2.12.1 Company Overview
- 3.2.12.2 Product Portfolio
- 3.2.12.3 Target Customers/End Users
- 3.2.12.4 Analyst View
- 3.2.13 Takeda
- 3.2.13.1 Company Overview
- 3.2.13.2 Product Portfolio
- 3.2.13.3 Target Customers/End Users
- 3.2.13.4 Analyst View
- 3.2.14 Pint Pharma
- 3.2.14.1 Company Overview
- 3.2.14.2 Product Portfolio
- 3.2.14.3 Target Customers/End Users
- 3.2.14.4 Analyst View
- 4. Research Methodology
- List of Figures
- Figure: Global Polycythemia Vera Market, Market Overview
- Figure: Global Polycythemia Vera Market, Epidemiological Analysis, U.S.
- Figure: Global Polycythemia Vera Market, Epidemiological Analysis, EU5
- Figure: Global Polycythemia Vera Market Coverage
- Figure: Global Polycythemia Vera Market Key Trends, Impact Analysis, 2023-2035
- Figure: Global Polycythemia Vera Market, Competitive Landscape, January 2022-April 2025
- List of Tables
- Table: Global Polycythemia Vera Market, Regulatory Scenario
- Table: Global Polycythemia Vera Market, Pipeline Analysis
- Table: Global Polycythemia Vera Market Dynamics, Impact Analysis
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook